|
|
| Volume 18 • Issue 4 |
February 21, 2018 |
 |
|
|
 |
| |
 |
|
|
FOQUEST: NOW AVAILABLE
Purdue Pharma announces the launch of FOQUEST®, a new product (methylphenidate
hydrochloride controlled release capsules), indicated for the treatment of Attention
Deficit Hyperactivity Disorder (ADHD) in adults (≥18 years of age).
Read more
|
|
|
|
| |
 |
|
|
NOW AVAILABLE
SUBOXONE® (BUPRENORPHINE AND NALOXONE): ONCE‑DAILY DOSING
SUBOXONE is now available in 12 mg and 16 mg tablets for substitution treatment in adults with problematic opioid drug dependence. Click here for more information on dosing and administration, and important safety information.
|
|
 |
| |
 |
|
|
IMPORTANT INFORMATION
TEMPORARY BACKORDER OF FLAGYL® CREAM 10%
(METRONIDAZOLE)
Sanofi-aventis Canada Inc. would like to inform you that Flagyl® Cream 10% (Metronidazole) will be on temporary backorder from the week of February 26th due to a supply issue for the active ingredient.
Read more
|
|
|
|
| |
|
|
|
IMPORTANT INFORMATION
TEMPORARY BACKORDER OF MYOCHRYSINE® 10 MG/ML
(SODIUM AUROTHIOMALATE)
Sanofi-aventis Canada Inc. would like to inform you that Myochrysine® 10 mg/mL (sodium aurothiomalate) is on temporary backorder due to a supply issue for the active ingredient.
Read more
|
|
 |
 |
| |
 |
|
|
COLD-FX® HAS A NEW DRESS CODE
Click here to see our redesigned packaging.
|
|
|
|
|
|
| |
 |
|
|
MANAGE CHOLESTEROL AND BLOOD PRESSURE
Read more
|
|
|
|
